NY-ESO-1 is a Ubiquitous Immunotherapeutic Target Antigen for Patients with Myxoid/ Round Cell Liposarcoma

BACKGROUND: Myxoid/ round cell liposarcoma (MRCL) is the second most common liposarcoma subtype, accounting for more than one third of liposarcomas and approximately 10% of all soft tissue sarcomas. Although MRCL is a chemosensitive subtype, patients with metastatic disease have a poor outcome. NY-E...

詳細記述

保存先:
書誌詳細
主要な著者: Pollack, Seth M., Jungbluth, Achim A., Hoch, Benjamin L., Farrar, Erik A., Bleakley, Marie, Schneider, David J., Loggers, Elizabeth T., Rodler, Eve, Eary, Janet F., Conrad, Ernest U., Jones, Robin L., Yee, Cassian
フォーマット: Artigo
言語:Inglês
出版事項: 2012
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3361576/
https://ncbi.nlm.nih.gov/pubmed/22359263
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.27446
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料